drugset / Trial / NCT02038777
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients. PF-04449913 will be administered orally as a single agent in patients with select advanced hematologic malignancies, or in combination with LDAC \[Low-Dose Ara-C\] or cytarabine and daunorubicin in previously untreated patients with AML \[Acute Myeloid Leukemia\] or high-risk MDS \[Myelodysplastic Syndrome\], or in combination with azacitidine in previously untreated patients with AML.
Timeline
- Start
- 2014-03-25
- Primary completion
- 2021-02-12
- Completion
- 2023-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glasdegib | Small molecule | — | Oral |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Background | Cytarabine | Small molecule | 20 mg | Subcutaneous |
| Background | Cytarabine | Small molecule | 100 mg/m2 | — |
| Background | Daunorubicin | Small molecule | 60 mg/m2 | — |